Chew Chee Kian, Clarke Bart L
Mayo Clinic E18-A, 200 1st Street SW, Rochester, MN, 55905 USA.
Mayo Clinic E18-A, 200 1st Street SW, Rochester, MN, 55905 USA.
Maturitas. 2017 Mar;97:53-60. doi: 10.1016/j.maturitas.2016.12.003. Epub 2016 Dec 15.
The treatment of osteoporosis is generally either by inhibition of bone resorption with antiresorptive agents or by stimulation of bone formation with anabolic agents. Currently, teriparatide (recombinant human parathyroid hormone 1-34 [rhPTH (1-34)]) is the only available approved anabolic agent in the U.S. Other anabolic agents are under investigation however. Abaloparatide is recombinant human parathyroid hormone-related peptide 1-34. This agent is an anabolic agent that appears more potent than teriparatide, and it may have more rapid onset of fracture reduction than teriparatide. It is currently undergoing FDA review, with approval expected in 2017.
骨质疏松症的治疗通常要么使用抗吸收剂抑制骨吸收，要么使用促合成剂刺激骨形成。目前，特立帕肽（重组人甲状旁腺激素1-34 [rhPTH(1-34)]）是美国唯一获批的促合成剂。不过，其他促合成剂正在研究中。阿巴洛帕肽是重组人甲状旁腺激素相关肽1-34。这种药物是一种促合成剂，似乎比特立帕肽更有效，而且其减少骨折的起效可能比特立帕肽更快。它目前正在接受美国食品药品监督管理局（FDA）的审评，预计2017年获批。
